Research Use Only

IHC Guaranteed Antibodies

Our IHC Guaranteed antibody range comprises over 400 primary antibodies validated for immunohistochemistry in formalin-fixed paraffin-embedded tissue sections. Used by researchers to study protein expression, cell identity and tumour biology across a wide range of tissue types and research applications.

Browse IHC Guaranteed Antibodies
400+
IHC antibodies validated in paraffin-embedded tissue sections
12
Research area categories from carcinoma to neuroendocrine
2014
First antibody supplier to host the International Antibody Validation Forum
1 year
Product guarantee on all antibodies

About IHC Guaranteed Antibodies

Selecting a reliable IHC antibody for paraffin-embedded tissue research requires confidence in specificity and reproducibility. Each antibody in this range has been tested by St John’s Laboratory scientists under defined IHC conditions, with results documented in the product datasheet so researchers can replicate the experiment without extensive optimisation.

The range covers key research targets across oncology, immunology, neuroscience, infectious disease and cell biology, all validated specifically in paraffin sections (IHC-P).

All products are for research use only and are not intended for diagnostic or therapeutic applications.

What the Datasheet Includes

  • Validated dilution range for paraffin-embedded tissue
  • Representative IHC images showing expression in positive tissue
  • Positive control tissue type used during validation
  • Species reactivity confirmed in paraffin sections
  • Clone name and immunogen details for cross-referencing
  • 1-year product guarantee
Choosing an IHC Antibody

Validated IHC Antibodies for Paraffin-Embedded Tissue

Paraffin-Embedded Tissue (IHC-P)

All antibodies in this range are validated in formalin-fixed paraffin-embedded sections, the most widely used tissue format in cancer biology and pathology research, enabling long-term archiving and retrospective studies.

Specificity in Complex Tissue

IHC in tissue sections requires antibodies that discriminate between target and off-target proteins across mixed cell populations. Each antibody in this range has been tested against positive control tissue to confirm specific staining.

Reproducibility First

As host of the 1st International Antibody Validation Forum in 2014, St John’s Laboratory has built this IHC antibody range with reproducibility as the primary selection criterion. Validation data is published in every datasheet.

Cocktail Panels Available

Selected targets are available as pre-formulated IHC antibody cocktails combining two or three markers in a single reagent, reducing tissue consumption and staining steps when working with limited biopsy material.

Carcinoma Research

IHC Antibodies for Carcinoma & Adenocarcinoma

IHC antibodies for site-of-origin identification and lineage characterisation in paraffin-embedded carcinoma tissue. Commonly used to investigate tumour biology across lung, bladder, thyroid, kidney and gastrointestinal research models. Key targets include epithelial cell adhesion molecules, transcription factors and receptor tyrosine kinases whose expression patterns have been well characterised in primary carcinoma tissue. These IHC antibodies are widely used in studies examining tumour heterogeneity, metastatic spread and the molecular basis of carcinoma subtype differences.

Haematology Research

IHC Antibodies for Lymphoma & Haematological Malignancy

CD marker and lineage IHC antibodies for lymphoma subtype characterisation, leukaemia cell phenotyping and immune cell localisation in lymphoid tissue research. Validated in paraffin-embedded tonsil, lymph node and bone marrow sections. These IHC antibodies are widely used to investigate cell surface receptor expression, B and T cell identity, and the composition of the immune microenvironment in haematological malignancy models. They support research into lymphoma biology, clonal expansion and the functional properties of tumour-infiltrating immune populations.

Cancer Biology

IHC Antibodies for Tumour Suppressors & Cell Cycle

Validated IHC antibodies for studying cell cycle regulation, apoptosis and tumour suppressor protein expression in paraffin-embedded tissue sections. Used across cancer biology research to characterise proliferative activity and oncogene expression. These antibodies enable researchers to assess cell cycle progression markers such as Ki-67 and Cyclin D1, pro- and anti-apoptotic proteins including BCL2 and BAX, and established tumour suppressors such as p53 and p16 in intact tissue architecture. They are commonly applied in studies examining growth control, DNA damage response and the molecular consequences of oncogene activation.

Epithelial Biology

Cytokeratin IHC Antibodies & Epithelial Markers

Cytokeratin IHC antibodies for characterising epithelial cell populations and identifying carcinoma origin in paraffin-embedded tissue. Includes pan-cytokeratin, high molecular weight cytokeratin and individual CK isoforms widely used in tissue-based research. Cytokeratin expression patterns are well-established tools for assessing epithelial differentiation state, studying epithelial-mesenchymal transition and distinguishing epithelial from stromal or haematological cell populations in mixed tissue sections. These IHC antibodies are routinely applied in studies of tumour invasion, metastasis and tissue organisation.

Melanoma & Soft Tissue Research

IHC Antibodies for Melanoma & Soft Tissue Tumours

IHC antibodies for investigating melanocytic differentiation and soft tissue tumour biology in paraffin-embedded sections. Used in melanoma research to characterise marker expression and study tumour cell identity and differentiation state. Targets include established melanocytic markers such as Melan-A, HMB-45, MITF and S-100, as well as muscle lineage proteins including Desmin used to study myogenic tumour differentiation. These IHC antibodies are applied in research examining melanoma progression, neural crest lineage biology and the molecular basis of soft tissue tumour classification.

Neuroendocrine Research

IHC Antibodies for Neuroendocrine & Neural Tumours

Neuroendocrine marker IHC antibodies for studying NE differentiation, neural lineage and tumour biology in paraffin sections. Widely used in research on neuroendocrine tumours, CNS tumours and peripheral neural tissue. Core neuroendocrine markers including Chromogranin A, Synaptophysin, NSE and INSM1 enable researchers to characterise secretory granule content, assess NE differentiation grade and study the molecular relationship between NE tumour subtypes. GFAP and NeuN IHC antibodies support parallel research into glial and neuronal cell identity in central and peripheral nervous system tissue.

Prostate Cancer Research

IHC Antibodies for Prostate Cancer Research

IHC antibodies for prostate cancer research validated in paraffin-embedded prostate tissue sections. Includes AMACR, PSA, ERG, androgen receptor and p40, which are markers widely studied to investigate prostate tumour biology and progression. These IHC antibodies are commonly used in studies examining androgen receptor signalling, basal and luminal cell identity, TMPRSS2-ERG gene fusion consequences and the molecular characteristics of high-grade prostatic intraepithelial neoplasia. They support research into prostate cancer initiation, progression and the biology of castration-resistant disease.

Breast & Gynaecological Research

IHC Antibodies for Breast & Gynaecological Research

IHC antibodies for breast and gynaecological cancer research validated in paraffin-embedded tissue. Commonly used to study hormone receptor expression, HER2 biology, and lineage markers in breast, ovarian and endometrial research models. These IHC antibodies support investigation of oestrogen and progesterone receptor biology, HER2 protein expression and amplification status, and transcription factors such as GATA3 that define luminal breast cell identity. Mammaglobin IHC antibodies are widely applied in research on metastatic spread from primary breast tumour sites.

Gastrointestinal Research

IHC Antibodies for Liver, GI & Pancreatic Research

IHC antibodies for investigating protein expression in liver, gastrointestinal and pancreatic tumour tissue. Includes markers used to study hepatocellular carcinoma biology, GI tumour differentiation and pancreatic endocrine cell function in paraffin sections. AFP, HepPar1 and GPC3 IHC antibodies are widely applied in research characterising hepatocellular versus cholangiocellular tumour biology, while CDX2 supports investigation of intestinal differentiation in GI and metastatic carcinoma models. Gastrin and Glutamine Synthetase IHC antibodies are used in studies of pancreatic and hepatic metabolic function.

Immuno-Oncology Research

IHC Antibodies for Immune Checkpoint Research

IHC antibodies for studying immune checkpoint protein expression in the tumour microenvironment. Used in immuno-oncology research to characterise PD-L1, PD-1 and CTLA-4 expression in paraffin-embedded tumour tissue sections. These IHC antibodies enable researchers to investigate the spatial distribution of immune checkpoint molecules within the tumour, stromal and immune cell compartments of complex tissue sections. They are widely applied in studies examining immune evasion mechanisms, T cell exhaustion, and the relationship between checkpoint protein expression patterns and the composition of tumour-infiltrating lymphocyte populations.

Infectious Disease Research

IHC Antibodies for Infectious Disease Research

IHC antibodies for in situ detection of viral and bacterial antigens in paraffin-embedded tissue. Used in infectious disease and pathology research to localise pathogen proteins within tissue architecture. Targets include EBV, CMV, HSV, HPV, H. pylori and Hepatitis B antigens, enabling researchers to study the spatial relationship between pathogen distribution and host tissue responses. These IHC antibodies are commonly applied in research examining viral oncogenesis, pathogen-induced tissue injury, and the histological consequences of infection in preclinical and archival tissue models.

Research Efficiency

IHC Antibody Cocktail Panels

Pre-formulated IHC antibody cocktails combining complementary markers in a single reagent for simultaneous detection on a single slide. Reduces tissue consumption and staining steps, which is particularly useful when working with limited biopsy material or archival tissue samples. Available combinations include prostate panels pairing AMACR with p63 and high molecular weight cytokeratin, breast panels combining p63 with CK8/18, lung panels pairing p40 with Napsin A, and lymphoid panels combining CD3 with CD20. These IHC antibody cocktails are designed to support research requiring co-localisation of complementary markers in the same tissue section.

Our Commitment to You

Validated in paraffin-embedded tissue sections

📋

Validation data and representative images in every datasheet

🔬

400+ IHC antibodies across 12 research areas

Free shipping available

365-day guarantee on all antibodies

Looking for a Specific IHC Antibody?

Browse the full IHC Guaranteed range of over 400 validated IHC antibodies across carcinoma, lymphoma, neuroendocrine, melanoma, infectious disease and more.

Browse IHC Guaranteed Antibodies
For Research Use Only. Not intended for use in diagnostic or therapeutic procedures.